Comparative Pharmacology
Head-to-head clinical analysis: INVELTYS versus MAXITROL.
Head-to-head clinical analysis: INVELTYS versus MAXITROL.
INVELTYS vs MAXITROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid; modulates inflammatory response by binding to glucocorticoid receptors, altering gene expression and suppressing pro-inflammatory cytokines.
Maxitrol is a combination of dexamethasone (corticosteroid), neomycin (aminoglycoside antibiotic), and polymyxin B (polymyxin antibiotic). Dexamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Neomycin binds to bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides.
Instill 1 drop into the affected eye(s) four times daily for 14 days, then taper as clinically indicated.
1-2 drops or 0.5-1 inch strip of ointment into the conjunctival sac every 4-6 hours; in severe cases, every 2-4 hours. Frequency may be reduced after improvement.
None Documented
None Documented
Approximately 1.5 hours (range 1-2 hours) for the ophthalmic suspension; terminal half-life in systemic circulation is about 3 hours after topical ocular administration.
Neomycin: 2–3 h (topical) but prolonged in renal impairment. Polymyxin B: 6–7 h (topical). Dexamethasone: 3–4 h (topical). Clinical: systemic absorption minimal with intact epithelium; half-life may be prolonged with corneal abrasion or inflammation.
Primarily hepatic metabolism with minimal renal excretion (<5% unchanged in urine). Fecal elimination accounts for approximately 20% of the dose.
Renal: neomycin 30–50%; polymyxin B <1%; dexamethasone <1%. Fecal: neomycin >50% (unabsorbed); polymyxin B >99% (unabsorbed); dexamethasone <5%. Biliary: negligible for all components.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination